EUVIMEDEUVIMED entdecken
VergleichsstudieMultizentrische StudieRandomisierte kontrollierte StudieOpen Access

Meningeal Embolization for Preventing Chronic Subdural Hematoma Recurrence After Surgery

Eimad Shotar, Bertrand Mathon, Henri Salle, Aymeric Rouchaud, Charbel Mounayer, Nicolas Bricout, Jean-Paul Lejeune, Kevin Janot, Aymeric Amelot, Olivier Naggara, Alexandre Roux, Stéphane Goutagny und 18 weitere

JAMA · 08.07.2025 · 334 (2) · 127

DOI: 10.1001/jama.2025.7583 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift JAMA, erschienen am 08.07.2025. Verfasst von Eimad Shotar und 29 weiteren Autor:innen. Beteiligte Einrichtung: APHP, Department of Neuroradiology, Pitié-Salpêtrière Hospital, Paris, France. Hauptthemen laut MEDLINE: Embolization, Therapeutic, Hematoma, Subdural, Chronic, Meningeal Arteries, Secondary Prevention. Die Arbeit wurde bisher 98-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Middle meningeal artery (MMA) embolization has been proposed as a potential treatment for chronic subdural hematoma (CSDH).

Objective

To assess the efficacy of MMA embolization in reducing the risk of CSDH recurrence at 6 months compared with standard care in patients who underwent an operation and were at high risk of CSDH recurrence. Design, Setting, and Participants Multicenter, open-label, randomized clinical trial with blinded end point assessment. Patients who underwent an operation for CSDH recurrence or a first CSDH episode at high risk of recurrence were recruited from July 2020 to March 2023 in 12 French neurosurgical or comprehensive neurosurgical and interventional neuroradiology centers. Last follow-up took place on November 2, 2023.

Intervention

Participants were randomized 1:1 to undergo MMA embolization with microparticles within 7 days of surgery (171 patients, intervention group) or standard medical care alone (171 patients, control group). Main Outcomes and Measures The primary end point was the rate of CSDH recurrence at 6 months assessed by an independent, blinded adjudication committee. There were 5 secondary end points, including rates of repeat surgery for homolateral CSDH recurrence during the 6-month follow-up period and embolization procedure–related complications.

Results

Among 342 randomized patients (median [IQR] age, 77 [68-83] years; 274 [80.1%] male), 308 (90.1%) completed the trial. The primary end point was observed in 24 of 162 (14.8%) and 33 of 157 (21.0%) patients in the intervention and control groups, respectively (after imputation: odds ratio, 0.64 [95% CI, 0.36-1.14]; adjusted absolute difference, −6% [95% CI, −14% to 2%]; P = .13). The groups did not significantly differ in any of the secondary end points. Repeat surgery was performed in 7 of 162 (4.3%) and 13 of 157 (8.3%) patients in the intervention and control groups ( P = .14), respectively. Minor and major embolization procedure–related complications occurred in 3 of 171 (1.8%) and 1 of 171 (0.6%) patients, respectively. Conclusions and Relevance In this randomized clinical trial, among patients who underwent an operation for CSDH recurrence or a first CSDH episode at high risk of recurrence, MMA embolization did not lead to a significantly lower rate of recurrence at 6 months compared with standard medical care alone. However, the magnitude of the effect estimate is consistent with other recent trials, including some that demonstrated the benefit of MMA embolization with nonadhesive liquid embolic agents, and these findings considered together may inform future studies and potential use of this therapeutic approach for CSDH management. Trial Registration ClinicalTrials.gov Identifier: NCT04372147

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Embolization, TherapeuticHematoma, Subdural, ChronicMeningeal ArteriesSecondary PreventionAgedAged, 80 and overFemaleHumansMaleRecurrenceReoperationTreatment Outcome

Autor:innen und Institutionen

  • APHP, Department of Neuroradiology, Pitié-Salpêtrière Hospital, Paris, France.
  • Sorbonne Université, INSERM, CNRS, Institut de la Vision, Paris, France.
  • Sorbonne University, Paris, France.
  • APHP, Department of Neurosurgery, Pitié-Salpêtrière Hospital, Paris, France.
  • Department of Neurosurgery, Limoges University Hospital, Limoges, France.
  • Department of Interventional Neuroradiology, EMIS Platform, Limoges University Hospital, F-87042, University of Limoges, XLIM, CNRS, UMR 7252, Limoges, France.

Zitieren

APA

Shotar, E., Mathon, B., Salle, H., Rouchaud, A., Mounayer, C., Bricout, N., Lejeune, J. P., Janot, K., Amelot, A., Naggara, O., Roux, A., Goutagny, S., Guédon, A., Houdart, E., Brunel, H., Hak, J. F., Troude, L., Dufour, H., Bernat, A. L., …, & EMPROTECT Investigators (2025). Meningeal Embolization for Preventing Chronic Subdural Hematoma Recurrence After Surgery. JAMA, 334(2), 127. https://doi.org/10.1001/jama.2025.7583

Vancouver

Shotar E, Mathon B, Salle H, Rouchaud A, Mounayer C, Bricout N, et al. Meningeal Embolization for Preventing Chronic Subdural Hematoma Recurrence After Surgery. JAMA. 2025;334(2):127. doi:10.1001/jama.2025.7583

BibTeX
@article{Shotar2025,
  author = {Shotar, Eimad and Mathon, Bertrand and Salle, Henri and Rouchaud, Aymeric and Mounayer, Charbel and Bricout, Nicolas and Lejeune, Jean-Paul and Janot, Kevin and Amelot, Aymeric and Naggara, Olivier and Roux, Alexandre and Goutagny, Stéphane and Guédon, Alexis and Houdart, Emmanuel and Brunel, Hervé and Hak, Jean-François and Troude, Lucas and Dufour, Henry and Bernat, Anne-Laure and Tuilier, Titien and Bresson, Damien and Apra, Caroline and Fouet, Mathilde and Escalard, Simon and Chauvet, Dorian and Premat, Kevin and Lebbah, Said and Dechartres, Agnès and Clarencon, Frédéric and EMPROTECT Investigators, EMPROTECT Investigators},
  title = {Meningeal Embolization for Preventing Chronic Subdural Hematoma Recurrence After Surgery},
  journal = {JAMA},
  year = {2025},
  volume = {334},
  number = {2},
  pages = {127},
  doi = {10.1001/jama.2025.7583}
}
Kostenlos starten →